None listed
Conditions
Interventions
Drug :
Both sedation medicine will inject through intravenously.
In the case of remimazolam group, the first 2.5 mg is injected, the maintenance dose is continuously administered to 0.2 mg/kg/hr, and
Sponsors
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who visit Eunpyeong St. Mary's Hospital and undergo TAVI through MAC aged 65 or older
Exclusion criteria
Exclusion criteria: A prospective patient with percutaneous aortic valve replacement under general anesthesia A preoperative delirious patient A patient over the age of ninety Left ventricular ejection fraction <30% Patients receiving preoperative circulatory support such as ECMO Patients with a recent myocardial infarction Patients with a history of allergies to dexmedetomidine, opioids, and benzodiazepines Patients with Contraindications for Use of Dexmedetomidine, Remifentanyl, and Remimazolam Patients receiving dialysis for end-stage renal failure Severe cirrhosis of Child-Pugh class C
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of blood pressure;amount of vasopressor;number of hypotension | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in hemodynamic indicators during surgery (cardiac index (CI), pulse pressure variation (PPV), stroke volume variation (SVV), Systemic vascular resistance index (SVRI), stroke volume index (SVI), and cardI index (CPI)) | — |
Countries
Korea, Republic of
Contacts
Public ContactSung Woo Hyung
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Outcome results
None listed